Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: Willsgarden who wrote (54207)	3/30/2006 9:15:14 AM
From: hotlinktuna	Read Replies (1) \| Respond to of 59879

VPHM helping gap up! Also CYGX 1.38 has good news: CytoGenix Receives First Order for synDNA(TM) Thursday March 30, 8:00 am ET HOUSTON--(BUSINESS WIRE)--March 30, 2006--CytoGenix, Inc. (OTCBB:CYGX - News) announced receiving its first purchase order for synDNA(TM) synthetic DNA. The order was placed by Aldevron (Fargo, North Dakota), a leading worldwide supplier of DNA for research and clinical applications. CytoGenix and Aldevron have joined forces to meet the special needs of the market for multi-gram quantities of highly pure DNA. ADVERTISEMENT "The CytoGenix synDNA(TM) technology allows us to offer a broader range of solutions to gene therapy and DNA vaccine researchers," said Dr. Michael Chambers, President and CEO of Aldevron. "One of our goals is to help expand the field of DNA-based pharmaceuticals. We welcome the relationship with CytoGenix and look forward to working together to expand the market for high quality DNA." Plasmid DNA is commonly used to make many copies of a particular gene. These genes are used by researchers to test DNA-based treatments for a wide range of diseases. Traditionally, plasmid DNA is manufactured via a complex process that involves processing bacteria to yield high-grade amounts of plasmid DNA. CytoGenix' product is produced synthetically, and no bacteria are required, thereby speeding the production time and increasing the purity and quality of the DNA. Dr. Malcolm Skolnick, President and CEO commented, "This is a major milestone for CytoGenix. While our primary goal is to develop our own products, we are pleased to service the growing need for high purity cost-effective DNA. We are very excited about our relationship with Aldevron and the opportunity to supply their needs for synDNA(TM)." About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 48 international or US pending patent applications claiming methods and materials in connection with this platform technology. SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com. Contact: CytoGenix, Inc., Houston Kurt Berens, 713-789-0070 -------------------------------------------------------------------------------- Source: CytoGenix, Inc. Hope we all have a good day!! tuna